OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights
15. März 2019 07:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results
07. März 2019 16:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals
05. Dezember 2018 08:10 ET
|
OncoMed Pharmaceuticals, Inc.
To be effected by an all-stock transaction plus issuance of Contingent Value Rights (“CVRs”); completion expected H1 2019 Deal broadens asset and shareholder base and extends Enlarged Group cash...
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
09. November 2018 08:00 ET
|
OncoMed Pharmaceuticals, Inc.
Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage Solid Tumors REDWOOD CITY, Calif. and WASHINGTON, Nov. 09,...
OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights
01. November 2018 16:05 ET
|
OncoMed Pharmaceuticals, Inc.
-Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer; -Prepares for presentation of etigilimab data at...
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
22. Oktober 2018 08:00 ET
|
OncoMed Pharmaceuticals, Inc.
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab REDWOOD CITY,...
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
20. Oktober 2018 06:30 ET
|
OncoMed Pharmaceuticals, Inc.
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab REDWOOD CITY,...
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting
09. Oktober 2018 08:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed to Present at the Cantor Global Healthcare Conference
24. September 2018 16:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Announces Publication of Phase 1a Data of Navicixizumab
24. September 2018 08:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...